Clinical trialNCT05922761RecruitingPhase 2Interventional

BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)

SponsorDana-Farber Cancer InstituteEnrollment45Bronchiolitis ObliteransBronchiolitis Obliterans SyndromeChronic Graft Versus Host DiseaseLung Diseases

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The goal of this research study is to test the efficacy of a novel immunosuppressive agent, belumosudil, in allogeneic hematopoietic stem cell transplant (HSCT) recipients who have been newly diagnosed or have developing (early stage) bronchiolitis obliterans syndrome (BOS). The name of the study drugs involved in this study are: * Belumosudil (an immunotherapy) * Fluticasone (an intranasal corticosteroid) * Azithromycin (an antibiotic) * Montelukast (a leukotriene receptor antagonist) * Prednisone (a corticosteroid)

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Corey Cutler, MD, MPH
Dana-Farber Cancer Institute
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Stanford University School of Medicine
Stanford, California, United States
Joe L Hsu, MD
Recruiting
Boston Children'S Hospital
Boston, Massachusetts, United States
Not, yet, recruiting
Brigham and Women'S Hospital
Boston, Massachusetts, United States
Not, yet, recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Corey Cutler, MD, MPH →
Recruiting
University of Michigan
Ann Arbor, Michigan, United States
Gregory A Yanik, MD, BS
Recruiting
Fred Hutchinson Cancer Center
Seattle, Washington, United States
Guang-Shing Cheng, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Azithromycin →Belumosudil →Fluticasone →Montelukast →Prednisone →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 May 2024
Primary completion: 30 Jun 2027
Completion: 31 Dec 2027
Last update posted: 10 Jun 2026
Registered enrollment: 45
Registry id: NCT05922761

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.